Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes - Kelly, R. P.; Garhyan, P.; Raddad, E.; Fu, H.; Lim, C. N.; Prince, M. J.; Pinaire, J. A.; Loh, M. T.; Deeg, M. A. (Diabetes, obesity & metabolism, 2015)
Keywords: Adult; Aged; Biphenyl Compounds - administration & dosage; Biphenyl Compounds - blood; Biphenyl Compounds - pharmacokinetics; Biphenyl Compounds - therapeutic use; Clinical trials; Cohort Studies; Cross-Over Studies; Diabetes; diabetes care; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Glucagon; Glucagon - agonists; Glucagon - blood; Glucagon - secretion; glucagon antagonist; Glucose; Glycated Hemoglobin A - analysis; Half-Life; Humans; Hyperglycemia - prevention & control; Hypoglycemia; Hypoglycemia - chemically induced; Hypoglycemia - epidemiology; Hypoglycemia - prevention & control; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Male; Middle Aged; Molecular Targeted Therapy - adverse effects; Oral administration; Patients; Pharmacodynamics; Pharmacokinetics; pharmacology; Receptors, Glucagon - antagonists & inhibitors; Risk; Single-Blind Method; pharmacokinetics; diabetes care; glucagon antagonist; pharmacology